Tag Archives: FDA

A boomerang drug

On June 7, the U.S. Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s Disease (AD), its first in nearly two decades. Manufactured by Biogen (a biotech company based in Cambridge, MA) and called Aduhelm, the drug was … Continue reading

Posted in Global Innovation, Health Care | Tagged , , , , , , | Leave a comment

All Innovation Is Local

I like this phrase: all politics is local. Ascribed to the late Speaker of the U.S. House of Representatives Tip O’Neill this phrase means that all political decisions, regardless of their purpose and scale, must take into account the interests … Continue reading

Posted in Health Care | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Should We Celebrate Failure Worth A Billion?

As every popular topic, innovation is a powerful magnet for clichés. Some of them obliterate more than illuminate. For example, I’m not sure that mixing innovation with DNA is a good idea. Though I kind of understand what Clayton Christensen … Continue reading

Posted in Portfolio Management | Tagged , , , , , , , | 11 Comments

A silver bullet that was not

There are lies, damned lies and statistics Alzheimer’s disease (AD) is a horrible illness. A progressive neurodegenerative disorder that destroys memory, abstract thinking and cognitive function, it’s the most common cause of dementia in humans, affecting as many as five … Continue reading

Posted in Health Care | Tagged , , , , , | Leave a comment

The Outsider Effect

Better decisions come from teams that include a “socially distinct newcomer”…someone who is different enough to bump other team member out of their comfort zones (From Kellog School of Management News, Embracing the “socially distinct outsider”) There are many things … Continue reading

Posted in Innovation | Tagged , , , , , , , | 2 Comments